A novel delivery system for continuous desferrioxamine infusion in transfusional iron overload.
Fifteen iron-overloaded thalassaemia major (TM) patients and two homozygous sickle cell patients (SCD) were treated continuously for 7d each week with the novel 48 h continuous subcutaneous (s.c.) desferrioxamine (DFX) delivery device (code C1083, Baxter) and 10 TM patients received the 24 h continuous intravenous (i.v.) DFX delivery device (code C1071). The 27 patients had previously received conventional s.c. DFX for 8-10h on 5 or more days each week. The serum non-transferrin bound iron (NTBI) levels fell significantly in both groups within 12h of commencing the continuous infusion. In the s.c. group the mean level fell from 4.2 to 2.0 mumol/l (P = 0.001), whereas in the i.v. group the mean level fell from 3.6 to 0.1 mumol/l (P = 0.006) the initial levels being measured 12h after stopping conventional s.c. DFX. After 4 weeks there was a significant fall in serum ferritin in both groups (P = 0.009). The new DFX delivery device is effective at removing toxicfree iron from plasma and reducing body iron. Moreover, it is preferred by patients with much improved compliance compared to the conventional s.c. DFX pump.
Araujo
A
A
Department of Haematology, Whittington Hospital, London.
Kosaryan
M
M
MacDowell
A
A
Wickens
D
D
Puri
S
S
Wonke
B
B
Hoffbrand
A V
AV
D000293:Adolescent; D000328:Adult; D000755:Anemia, Sickle Cell / Q000097:blood / Q000150:complications; D003676:Deferoxamine / Q000008:administration & dosage*; D016503:Drug Delivery Systems; D005260:Female; D005293:Ferritins / Q000097:blood; D006486:Hemosiderosis / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D008297:Male; D017086:beta-Thalassemia / Q000097:blood / Q000150:complications
D005293:Ferritins; D003676:Deferoxamine